Your browser doesn't support javascript.
loading
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin, Lutz; Distler, Jörg H W; Redente, Elizabeth F; Riches, David W H; Stowasser, Susanne; Schlenker-Herceg, Rozsa; Maher, Toby M; Kolb, Martin.
Affiliation
  • Wollin L; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany stefan-lutz.wollin@boehringer-ingelheim.com.
  • Distler JHW; Dept of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany.
  • Redente EF; Program in Cell Biology, Dept of Pediatrics, National Jewish Health, Denver, CO, USA.
  • Riches DWH; Program in Cell Biology, Dept of Pediatrics, National Jewish Health, Denver, CO, USA.
  • Stowasser S; University of Colorado School of Medicine, Aurora, CO, USA.
  • Schlenker-Herceg R; Boehringer Ingelheim International GmbH, Ingelheim, Germany.
  • Maher TM; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
  • Kolb M; National Heart and Lung Institute, Imperial College London, London, UK.
Eur Respir J ; 54(3)2019 09.
Article in En | MEDLINE | ID: mdl-31285305
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lung Diseases, Interstitial / Idiopathic Pulmonary Fibrosis / Indoles / Lung Aspects: Patient_preference Limits: Animals / Humans Language: En Journal: Eur Respir J Year: 2019 Document type: Article Affiliation country: Germany Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lung Diseases, Interstitial / Idiopathic Pulmonary Fibrosis / Indoles / Lung Aspects: Patient_preference Limits: Animals / Humans Language: En Journal: Eur Respir J Year: 2019 Document type: Article Affiliation country: Germany Country of publication: United kingdom